Drug synthesis by genetically engineered microorganisms.

摘要: The interplay between chemical and biological approaches to drug discovery development is increasing with the advent of combinatorial methods that accelerate output screening programs genetically modified microorganisms able make new metabolites larger amounts known ones. Actinomycetes, most prolific microbial source drugs, can produce aromatic compounds by manipulation Type II polyketide synthase genes as well analogs existing macrolide antibiotics, unavailable synthesis, through targeted mutation specific biosynthetic genes. Genetic alteration pathways aminoglycoside oligopeptide antibiotics should offer equally promising manufacturing novel metabolites. When coupled DNA–based prescreening isolates for associated pharmacologically active agents, these genetic–based are creating an expanded role in research.